Moa of clonidine and methyl dopa
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive information from multiple authoritative textbooks. Here's a clear breakdown:
Mechanism of Action: Clonidine & Methyldopa
Both are centrally acting sympatholytic antihypertensives, but they differ in how they achieve this.
Clonidine
Class: Centrally acting α₂-adrenergic agonist (also acts on imidazoline receptors)
MOA:
- Clonidine binds to presynaptic α₂-adrenergic receptors in the brainstem, particularly in the nucleus tractus solitarius (NTS) and rostral ventrolateral medulla
- This inhibits norepinephrine release from noradrenergic neurons
- The result is a reduction in central sympathetic outflow → decreased heart rate, decreased vascular resistance, and lowered blood pressure
- Clonidine also acts on imidazoline receptors, which contribute to its sedating and hypotensive effects
- It is a relatively non-selective α₂ agonist, acting on α₂A, α₂B, and α₂C subtypes
Net effect: ↓ peripheral vascular resistance + ↓ venous tone + bradycardia
Methyldopa (α-Methyldopa)
Class: Centrally acting α₂ sympathetic agonist (prodrug)
MOA:
- Methyldopa is a prodrug — it is taken up into central adrenergic neurons and converted to α-methylnorepinephrine (a false neurotransmitter)
- α-Methylnorepinephrine then acts as an α₂ receptor agonist in the brainstem (just like clonidine), inhibiting sympathetic outflow
- Additionally, it works by depleting nerve terminal norepinephrine, reducing peripheral sympathetic tone
- This leads to decreased peripheral vascular resistance and venous constriction
Net effect: ↓ peripheral resistance + ↓ norepinephrine at nerve terminals → reduced BP
Side-by-Side Comparison
| Feature | Clonidine | Methyldopa |
|---|---|---|
| Drug type | Direct α₂ agonist | Prodrug → false transmitter |
| Site of action | NTS, brainstem α₂ receptors | Brainstem α₂ receptors (via α-methylNE) |
| Key mechanism | ↓ NE release centrally | Replaces NE with weaker false transmitter |
| Also acts on | Imidazoline receptors | — |
| Toxicity | Sedation, dry mouth, rebound HTN on withdrawal | Hemolytic anemia, sedation, orthostatic hypotension |
| Use in pregnancy | Yes (less data) | Yes (drug of choice historically) |
Key shared principle: Both drugs reduce blood pressure by activating central α₂ receptors in the brainstem → suppression of sympathetic outflow → ↓ heart rate and ↓ vascular resistance.
— Morgan and Mikhail's Clinical Anesthesiology, 7e | Katzung's Basic and Clinical Pharmacology, 16e | Creasy & Resnik's Maternal-Fetal Medicine | ROSEN's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.